Q-omics provides the consensus-scored UNC119B profile across patient tissues and cancer cell-line models. UNC119B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, UNC119B is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, UNC119B RNA expression shows 20,486 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, and ACC as cancer lineages where UNC119B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UNC119B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UNC119B survival associations across molecular data types. UNC119B RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UNC119B RNA expression–survival associations across cancer types. High UNC119B expression shows unfavorable associations in LIHC and ACC, but favorable associations in KIRC, UCS, PAAD and STAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for UNC119B RNA expression.
This table summarizes UNC119B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for UNC119B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UNC119B shows lower tumor expression in THCA, LUAD and BRCA and higher tumor expression in LIHC, HNSC and CHOL. The LIHC box plot shows higher UNC119B RNA expression in tumor versus normal tissue (log2 FC = +1.950, t-test p < 0.001).
This table shows molecular features associated with UNC119B in patient tissues and cancer cell lines. In patient samples, UNC119B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, UNC119B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
